Cue Biopharma

Yahoo Finance • last year

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

BOSTON, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it w... Full story

Yahoo Finance • last year

Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it w... Full story

Yahoo Finance • last year

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023

Overall response rate (ORR) of 47% and disease control rate (DCR) of 65% in first line (1L) recurrent/metastatic HNSCC patients treated with CUE-101 and KEYTRUDA® (pembrolizumab) ORR of 56% in patients with low expression of PD-L1 in the... Full story

Yahoo Finance • last year

Cue Biopharma to Host Business Update Call and Webcast

BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it w... Full story

Yahoo Finance • last year

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directl... Full story

Yahoo Finance • last year

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®

Completed enrollment of patient expansion cohort of 20 patients at the RP2D of 4 mg/kg in combination with KEYTRUDA® (pembrolizumab) in first line (1L) refractory/metastatic HPV+ Head and Neck Cancer patientsData to date from CUE-101 in co... Full story

Yahoo Finance • last year

Cue Biopharma to Present at the Federation of Clinical Immunology Societies (FOCIS) 2023 Annual Meeting

BOSTON, June 14, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly... Full story

Yahoo Finance • 2 years ago

Cue Biopharma to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Company to host Investor Update call on June 14, 2023 to review and discuss the clinical progress and associated data presented at ASCO BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biophar... Full story

Yahoo Finance • 2 years ago

Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly... Full story

Yahoo Finance • 2 years ago

Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors

BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directl... Full story

Yahoo Finance • 2 years ago

Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors

BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directl... Full story

Yahoo Finance • 2 years ago

Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Received U.S. Food and Drug Administration (FDA) acceptance of Investigational New Drug (IND) application for CUE-102 in Wilms’ Tumor 1 (WT1)-expressing cancers and initiated dosing in a Phase 1 dose escalation monotherapy trial at 1mg/kg.... Full story

Yahoo Finance • 2 years ago

Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences

BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directl... Full story

Yahoo Finance • 2 years ago

Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401

BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly... Full story

Yahoo Finance • 2 years ago

Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting

Collaboration with the laboratory of Dr. Michael Dustin elucidates the mechanism of action of Immuno-STATs in activating disease-specific T cells by mimicking the natural formation of immune synapses BOSTON, Feb. 16, 2023 (GLOBE NEWSWIR... Full story

Yahoo Finance • 2 years ago

Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board

BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly... Full story

Yahoo Finance • 2 years ago

Cue Biopharma to Present at Two February 2023 Scientific Conferences

BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly... Full story

Yahoo Finance • 2 years ago

Cue Biopharma Announces Chief Medical Officer Transition

Matteo Levisetti, M.D., promoted to Chief Medical Officer, effective January 17, 2023Acting CMO Kenneth Pienta, M.D., to transition to a clinical advisory role BOSTON, Jan. 23, 2023 (GLOBE NEWSWIRE) --  Cue Biopharma, Inc. (Nasdaq: CUE)... Full story

Yahoo Finance • 2 years ago

Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing

BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly w... Full story

Yahoo Finance • 2 years ago

Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Overall response rate (ORR) of 40% and a clinical benefit rate (CBR) of 70%observed to date in first line (1L) recurrent/metastatic HNSCC patients treated with CUE-101 at the recommended Phase 2 dose and pembrolizumab.Median overall surviv... Full story